摘要
目的研究晚期胃癌患者给予阿帕替尼联合化疗治疗的临床效果.方法选择晚期胃癌患者作为本次研究对象,并采用电脑随机法将80例晚期胃癌患者进行分组,主要包括两组,其中观察组实施阿帕替尼联合化疗治疗;对照组实施化疗治疗,分析两组PFS、OS指标、不良反应情况以及各项临床指标.结果观察组晚期胃癌患者PFS(3.61±0.21)个月、OS(9.54±1.32)个月长于对照组,两者差异有统计学意义(P<0.05).观察组晚期胃癌患者不良反应发生率2.50%低于对照组,差异有统计学意义(P<0.05).观察组晚期胃癌患者CA19-9(4.52±1.31)U·ml^-1、CEA(1.92±0.21)ng·ml^-1、TSGF(54.21±1.33)U·ml^-1均低于对照组,差异有统计学意义(P<0.05).结论晚期胃癌患者给予阿帕替尼联合化疗治疗效果显著,且安全性极高,值得研究.
Objective To study the clinical effect of apatinib combined with chemotherapy in patients with advanced gastric cancer. Methods Patients with advanced gastric cancer were selected as study subjects. 80 patients with advanced gastric cancer were divided into two groups by computer randomization method, including two groups. The observation group was treated with apatinib combined with chemotherapy, the control group was treated with chemotherapy, analysis of PFS, OS indicators, adverse reactions and various clinical indicators. Results In the observation group, PFS (3.61±0.21) months and OS (9.54±1.32) months were longer than the control group, and the difference was statistically significant (P<0.05). The incidence of adverse reactions in the patients with advanced gastric cancer in the observation group was 2.50% lower than that in the control group, and the difference was statistically significant (P<0.05). In the observation group, patients with advanced gastric cancer CA19-9 (4.52±1.31) U· ml^-1, CEA (1.92±0.21) ng·ml^-1, TSGF (54.21±1.33) U·ml^-1 were lower than the control group, the difference was statistical significance (P<0.05). Conclusion Patients with advanced gastric cancer are treated with apatinib in combination with chemotherapy, and the safety is extremely high, which is worthy of study.
作者
殷婷
杨建奇
陆园园
Yin Ting;Yang Jianqi;Lu Yuanyuan(Department of Oncology, Jiangsu Subei People' s Hospital, Yangzhou, Jiangsu, 225001, China)
出处
《当代医学》
2019年第25期66-68,共3页
Contemporary Medicine
关键词
晚期胃癌
阿帕替尼
化疗治疗
临床效果
Advanced gastric cancer
Apatinib
Chemotherapy treatment
Clinical effect